Tempus expands multi-year deals with Moderna and Merck

Tempus announced an expanded multi-year collaboration with Moderna and Merck aimed at supporting potential commercialization of intismeran autogene (V940/mRNA—4157) with KEYTRUDA, including sample logistics and, subject to approvals, NGS services. Financial terms were not disclosed.